Results 11 to 20 of about 5,159 (158)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia

Patient Preference and Adherence, 2018
Constantine E Kosmas,1 Delia Silverio,2 Julio Ovalle,2 Peter D Montan,2 Eliscer Guzman3 1Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, NY, USA; 2Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA; 3Division ...
Kosmas CE, Silverio D, Ovalle J, Montan PD, Guzman E   +4 more
doaj   +1 more source

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

Drug Design, Development and Therapy, 2017
Dave L Dixon,1 Leo F Buckley,1 Cory R Trankle,2 Dinesh Kadariya,3 Antonio Abbate2 1Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, 2Pauley Heart Center, 3Department of Internal Medicine, School of Medicine, Virginia Commonwealth ...
Dixon DL, Buckley LF, Trankle CR, Kadariya D, Abbate A   +4 more
doaj   +1 more source

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

Upsala Journal of Medical Sciences
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials.
Maria K. Svensson, Stefan James, Annica Ravn-Fischer, Guillermo Villa, Lovisa Schalin, Thomas Cars, Stefan Gustafsson, Emil Hagström   +7 more
doaj   +2 more sources

Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study [PDF]

Therapeutic Advances in Cardiovascular Disease
Aims: The HEYMANS study observed patients receiving evolocumab as part of routine clinical hyperlipidemia management. It was designed to capture data on clinical parameters relevant to health authorities and physicians. Methods: This was a European multi-
Isabella Sudano, Stephan Krähenbühl, François Mach, Anne Anstett, Nafeesa Dhalwani, Ian Bridges, Mahendra Sibartie, Kausik K. Ray   +7 more
doaj   +2 more sources

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

Lipids in Health and Disease, 2020
Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as ...
Xiang Zhang, Lotte C. A. Stiekema, Erik S. G. Stroes, Albert K. Groen   +3 more
doaj   +2 more sources

EXPERIENCE WITH THE USE OF EVOLOCUMAB THERAPY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (IN KARELIA REPUBLIC)

Евразийский Кардиологический Журнал, 2020
Aim: to evaluate the efficacy and safety of the use of evolocumab in patients with familial hypercholesterolemia (FH).Materials and methods: Fifteen patients with a definite FH were treated with PCSK9 inhibitors, in 11 patients with a history of CAD ...
V. A. Korneva, T. Yu. Kuznetsova, N. N. Natal’ya N. Vezikova   +2 more
doaj   +2 more sources

Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats

Pathophysiology
Background/Objectives: Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to low-density lipoprotein (LDL) receptors, thus allowing more LDL receptors to remove LDL cholesterol from the blood.
Martina Cebova, Radoslava Bulkova, Olga Pechanova   +2 more
doaj   +2 more sources

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins

Atherosclerosis Plus
Background and aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators.
Chaoxuan Wang, Anne Kaufmann, Nadja Kampschulte, Ulf Elbelt, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Anne Pietzner, Christoph Schmöcker, Dev Datta, Tiziana Sanpietro, Nils Helge Schebb, Karsten-H. Weylandt, Nadine Rohwer   +12 more
doaj   +2 more sources

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

Vascular Health and Risk Management, 2016
Courtney A Henry, Ronald A Lyon, Hua Ling Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, VA, USA Abstract: Multiple categories of medications have been developed to manage lipid profiles and reduce the risk of ...
Henry CA, Lyon RA, Ling H
doaj   +1 more source

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. [PDF]

J Cell Mol Med
ABSTRACT Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH).
Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E.   +5 more
europepmc   +2 more sources